J Lysholm
About
In The Last Decade
J Lysholm
18 papers receiving 957 citations
Peers
Comparison fields: 5 of 63
- Rheumatology 613
- Immunology 273
- Hematology 232
- Infectious Diseases 206
- Epidemiology 178
Countries citing papers authored by J Lysholm
This map shows the geographic impact of J Lysholm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Lysholm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Lysholm more than expected).
Fields of papers citing papers by J Lysholm
This network shows the impact of papers produced by J Lysholm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Lysholm. The network helps show where J Lysholm may publish in the future.
Co-authorship network of co-authors of J Lysholm
This figure shows the co-authorship network connecting the top 25 collaborators of J Lysholm. A scholar is included among the top collaborators of J Lysholm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Lysholm. J Lysholm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 5 | |
| 2 | 2 | |
| 3 | 19 | |
| 4 | 18 | |
| 5 | 18 | |
| 6 | 18 | |
| 7 | 197 | |
| 8 | 262 | |
| 9 | TNF-antagonist treatment and risk of hospitalisation for cardiovascular disease. Results from the National Swedish Monitoring-Program for Biologies in Ra (ARTIS). | 0 |
| 10 | TNF-antagonist treatment and risk of hospitalisation for infection. Results from the National Swedish Monitoring-Program for Biologics in RA (ARTIS). | 1 |
| 11 | Risk of tuberculosis in rheumatoid arthritis and following anti-TNF treatment. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA | 3 |
| 12 | Risk of cardiovascular morbidity and mortality following TNF-blockade. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA | 2 |
| 13 | 312 | |
| 14 | Safety and efficacy of adalimumab in arthritis patients previously treated with another biologic agent | 2 |
| 15 | A national database for co-morbidity in RA to evaluate drug safety. Solid cancers in RA and following anti-TNF treatment | 0 |
| 16 | Risk for lymphomas following TNF-blockade. Comparisons with a nationwide co-morbidity database | 1 |
| 17 | 101 | |
| 18 | 22 | |
| 19 | 4 | |
| 20 | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.